Literature DB >> 16181844

Pulmonary resection after high-dose and low-dose chest irradiation.

Robert James Cerfolio1, Ayesha S Bryant, Sharon A Spencer, Alfred A Bartolucci.   

Abstract

BACKGROUND: The purpose of this study is to assess the safety and efficacy of pulmonary resection after low and high dose neoadjuvant radiotherapy with concurrent chemotherapy. PATIENTS AND METHODS: A retrospective cohort study using an electronic prospective database from January 1998 to August 2004. All patients had N2, stage IIIa, nonsmall cell lung cancer, and received neoadjuvant carboplatinum-based chemotherapy with similar doses. In addition, some patients received high-dose chest radiation (HD) equal to or greater than 60 Gy and were compared with those who received low-dose radiation (LD) less than 60 Gy. All bronchial stumps were buttressed with an intercostal muscle.
RESULTS: There were 104 patients, 50 in the LD group and 54 patients in the HD group. Median dose of radiation was 45 Gy (range 35-50.4) in the LD group and 60 Gy (range 60-66.7) in the HD group. Complete pathologic response rate was 10% compared to 28% favoring the HD group (p = 0.04). Median length of stay for both groups was 4 days and the ICU was avoided in 74%. Major morbidity and mortality rates were similar: 8% compared to 9% and 2% compared to 3.7% for the low and high dose groups, respectively. Pneumonectomy was a significant risk factor for morbidity (OR = 17.0).
CONCLUSIONS: Pulmonary resection after preoperative chest radiation is safe even after 60 Gy or higher. Sixty or higher may afford an increase in complete pathologic response and it does not seem to increase morbidity or mortality. However, if pneumonectomy is known to be required we prefer to avoid neoadjuvant radiotherapy and use chemotherapy alone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16181844     DOI: 10.1016/j.athoracsur.2005.02.091

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  15 in total

1.  Clinical benefit of neoadjuvant chemoradiotherapy for the avoidance of pneumonectomy; assessment in 12 consecutive centrally located non-small cell lung cancers.

Authors:  Keizo Misumi; Hiroaki Harada; Norifumi Tsubokawa; Yasuhiro Tsutani; Kotaro Matsumoto; Yoshihiro Miyata; Yoshinori Yamashita; Morihito Okada
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-04-21

2.  Pulmonary resection after chemoradiotherapy for advanced non-small cell lung cancer: the impact of presurgical radiation therapy.

Authors:  Takeshi Shiraishi; Masafumi Hiratsuka; Jun Yanagisawa; Sou Miyahara; Yasuhiro Yoshida; Yoshifumi Makimoto; Daisuke Hamatake; Shin-ichi Yamashita; Akinori Iwasaki
Journal:  Surg Today       Date:  2013-02-19       Impact factor: 2.549

Review 3.  Neoadjuvant radiotherapy/chemoradiotherapy in locally advanced non-small cell lung cancer.

Authors:  Deniz Yalman
Journal:  Balkan Med J       Date:  2015-01-01       Impact factor: 2.021

4.  Management and postoperative outcome in primary lung cancer and heart disease co-morbidity: a systematic review and meta-analysis.

Authors:  George D Bablekos; Antonis Analitis; Stylianos A Michaelides; Konstantinos A Charalabopoulos; Anastasia Tzonou
Journal:  Ann Transl Med       Date:  2016-06

5.  Induction chemoradiotherapy using docetaxel and cisplatin with definitive-dose radiation followed by surgery for locally advanced non-small cell lung cancer.

Authors:  Hidejiro Torigoe; Junichi Soh; Shuta Tomida; Kei Namba; Hiroki Sato; Kuniaki Katsui; Katsuyuki Hotta; Kazuhiko Shien; Hiromasa Yamamoto; Masaomi Yamane; Susumu Kanazawa; Katsuyuki Kiura; Shinichiro Miyoshi; Shinichi Toyooka
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

Review 6.  Advances in multimodal treatment for stage IIIA-N2 non-small cell lung cancer.

Authors:  Sara Montemuiño Muñiz; Soraya Marcos Sánchez; Julia Calzas Rodríguez; Beatriz Losada Vila; Esther Llorente Herrero; María Dolores Hisado Díaz; Victoria Valeri-Busto González; Begoña Taboada Valladares; Blanca Vaquero Barrón; Francisco José Marcos Jimenez; Sergio Amor Alonso; Javier Moradiellos; Núria Rodríguez de Dios; Felipe Couñago
Journal:  J Clin Transl Res       Date:  2021-04-16

7.  High-dose neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery in potentially-resectable stage IIIA-N2 NSCLC. A multi-institutional retrospective study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society).

Authors:  Sara Montemuiño; Núria Rodriguez de Dios; Margarita Martín; Begoña Taboada; Patricia Calvo-Crespo; María Pilar Samper-Ots; José Luis López-Guerra; M López-Mata; Josep Jové-Teixidó; Verónica Díaz-Díaz; Lourdes de Ingunza-Barón; Mauricio Murcia-Mejía; Marisa Chust; Tamara García-Cañibano; María Luz Couselo; María Mar Puertas; Elia Del Cerro; Javier Moradiellos; Sergio Amor; A Varela; I J Thuissard; David Sanz-Rosa; Felipe Couñago
Journal:  Rep Pract Oncol Radiother       Date:  2020-03-18

8.  Surgical complications and clinical outcomes after dose-escalated trimodality therapy for non-small cell lung cancer in the era of intensity-modulated radiotherapy.

Authors:  Kevin X Liu; Kailan Sierra-Davidson; Kevin Tyan; Lawrence T Orlina; J Paul Marcoux; Benjamin H Kann; David E Kozono; Raymond H Mak; Abby White; Lisa Singer
Journal:  Radiother Oncol       Date:  2021-10-22       Impact factor: 6.280

Review 9.  Multidisciplinary team approach for the management of patients with locally advanced non-small cell lung cancer: searching the evidence to guide the decision.

Authors:  In-Jae Oh; Sung-Ja Ahn
Journal:  Radiat Oncol J       Date:  2017-03-31

Review 10.  How to evaluate the risk/benefit of trimodality therapy in locally advanced non-small-cell lung cancer.

Authors:  H Kunitoh; K Suzuki
Journal:  Br J Cancer       Date:  2007-05-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.